3-deazaneplanocin has been researched along with Melanoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hosokawa, M; Kono, Y; Ogawara, KI; Tetsumoto, S; Yasui, M | 1 |
| Donovan, NC; Hoon, DSB; Irie, RF; Tanaka, R; Yu, Q | 1 |
2 other study(ies) available for 3-deazaneplanocin and Melanoma
| Article | Year |
|---|---|
3-deazaneplanocin A, a histone methyltransferase inhibitor, improved the chemoresistance induced under hypoxia in melanoma cells.
Topics: Animals; Cell Line, Tumor; DNA Methylation; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Enzyme Inhibitors; Histone Methyltransferases; Histones; Humans; Irinotecan; Melanoma; Mice; RNA, Small Interfering; Tumor Microenvironment | 2023 |
Tumor necrosis factor-α and apoptosis induction in melanoma cells through histone modification by 3-deazaneplanocin A.
Topics: Adenosine; Adenosylhomocysteinase; Apoptosis; Cell Line, Tumor; Histones; Humans; Melanoma; Skin Neoplasms; Tumor Necrosis Factor-alpha | 2014 |